August 12th, 2010
CRESCENDO: The Fat Lady Sings for Rimonabant
Larry Husten, PHD
The CRESCENDO (Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes) trial, which tested the effects of the endocannabinoid receptor blocker rimonabant for the prevention of cardiovascular events, was terminated early at the request of regulatory agencies in several countries following growing concern that people taking rimonabant were more likely to commit suicide. At the […]
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024